Eli lilly logo

Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone

April 19, 2021

Eli Lilly has asked the FDA to revoke the Emergency Use Authorization for its monoclonal antibody bamlanivimab as a monotherapy for COVID-19 patients, but said the request was not due to any new safety concerns.

Bamlanivimab in combination with another Lilly antibody, etesevimab, has proven to be a more effective treatment, including against variant strains of the SARS-CoV-2 virus that causes COVID-19 infections.

Eli Lilly and the U.S. government have reworked their supply deal to deliver bamlanivimab only in combination with etesevimab.

View today's stories